An article from
Dive Brief
A revamped regulatory framework may give investors less of a “guessing game” as they weigh chances for drug approvals, one analyst said.
Published Oct. 15, 2026
First published on
Dive Brief:
- The Food and Drug Administration on Wednesday said it plans to “reimagine” the way it regulates therapies for rare diseases, looking at standards for individual conditions instead of a one-size-fits-all approach.
- The “Rare Disease Framework Initiative” will review existing policies, seek input from patients and experts and come up with a “fit-for-purpose framework” for drug development and regulation, the FDA said. Officials plan to look at everything from pre-clinical trial engagement through post-marketing requirements, the agency said in a white paper.
- Although the FDA didn’t set a timeline for initial recommendations for the new guidelines, Bloomberg News reported it’s targeting February. The agency will solicit feedback on the plan at a meeting on Oct. 28 on the FDA campus in Silver Spring, Maryland.
Dive Insight:
Attempting to bring new medicines to market is an inherently risky endeavor, with sponsors ultimately failing more than 90% of the time. But rare disease development is even harder; there are fewer patients available for research and less knowledge about both the condition and potential biomarkers that can serve as endpoints for a trial.
That has often left regulators in a quandary as they try to weigh the routine demand for clear evidence of safety and efficacy against the need for new treatments for devastating conditions. Peter Marks, the former head of the FDA’s drug evaluation center, was a champion for many of these rare disease drugs but also faced blowback from critics who suggested the agency had become too flexible.
One of those critics was Vinay Prasad, who took over the FDA’s biologics center in 2025. Under President Trump, Prasad and former FDA Commissioner Marty Makary talked about trying to help rare disease drug developers while taking a series of harder-line stances that confused and frustrated the industry as well as patient advocates.
Both Prasad and Makary are now gone, and the FDA is still waiting for a permanent leader. But the agency has since reversed several of the decisions that drew fire from the industry. The latest initiative continues this ongoing “reset” and may remove even more of the uncertainty that marked their tenure, Leerink Partners analyst Joseph Schwartz wrote in a note to clients.
“FDA is not lowering the bar for rare disease, but it may be making the path to approval less of a guessing game,” Schwartz wrote. If the plan turns into a “durable framework, it could join the list of FDA initiatives that investors might take for granted but have made biotech more investable.”
Past programs such as the orphan drug designation and priority review vouchers have created meaningful positive momentum for the industry, he said.
Some 30 million Americans live with a rare disease, according to the FDA. But as of last year, only about 5% of recognized rare conditions had an approved treatment.